1. Home
  2. CRMD vs DNTH Comparison

CRMD vs DNTH Comparison

Compare CRMD & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRMD
  • DNTH
  • Stock Information
  • Founded
  • CRMD 2006
  • DNTH 2015
  • Country
  • CRMD United States
  • DNTH United States
  • Employees
  • CRMD N/A
  • DNTH N/A
  • Industry
  • CRMD Biotechnology: Pharmaceutical Preparations
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRMD Health Care
  • DNTH Health Care
  • Exchange
  • CRMD Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • CRMD 925.6M
  • DNTH 1.0B
  • IPO Year
  • CRMD 2010
  • DNTH N/A
  • Fundamental
  • Price
  • CRMD $12.94
  • DNTH $37.16
  • Analyst Decision
  • CRMD Strong Buy
  • DNTH Strong Buy
  • Analyst Count
  • CRMD 8
  • DNTH 9
  • Target Price
  • CRMD $17.57
  • DNTH $61.57
  • AVG Volume (30 Days)
  • CRMD 4.6M
  • DNTH 962.6K
  • Earning Date
  • CRMD 10-29-2025
  • DNTH 11-06-2025
  • Dividend Yield
  • CRMD N/A
  • DNTH N/A
  • EPS Growth
  • CRMD N/A
  • DNTH N/A
  • EPS
  • CRMD 0.79
  • DNTH N/A
  • Revenue
  • CRMD $121,484,498.00
  • DNTH $4,854,000.00
  • Revenue This Year
  • CRMD $404.81
  • DNTH N/A
  • Revenue Next Year
  • CRMD $56.11
  • DNTH N/A
  • P/E Ratio
  • CRMD $16.35
  • DNTH N/A
  • Revenue Growth
  • CRMD 14970.29
  • DNTH 17.87
  • 52 Week Low
  • CRMD $5.60
  • DNTH $13.37
  • 52 Week High
  • CRMD $17.43
  • DNTH $38.59
  • Technical
  • Relative Strength Index (RSI)
  • CRMD 49.60
  • DNTH 83.51
  • Support Level
  • CRMD $12.73
  • DNTH $22.81
  • Resistance Level
  • CRMD $13.83
  • DNTH $24.81
  • Average True Range (ATR)
  • CRMD 0.75
  • DNTH 2.67
  • MACD
  • CRMD -0.16
  • DNTH 1.45
  • Stochastic Oscillator
  • CRMD 40.24
  • DNTH 90.94

About CRMD CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: